[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) – Form 4 insider transaction. 10% owner Richard Ian Griffiths reported a series of open-market purchases of the company’s American Depositary Shares (ADSs) between 22 and 24 June 2025.

• Griffiths bought 20,977 ADS at $5.84 on 22 Jun, 35,005 ADS at $5.88 on 23 Jun and 26,624 ADS at $6.12 on 24 Jun, totalling 82,606 ADS.
• At the stated prices, the aggregate consideration is approximately US $0.49 million.
• Each ADS represents three ordinary shares; the purchases therefore add about 247,818 ordinary shares to the insider’s economic exposure.
• Following the transactions, Griffiths’ direct holding increased to 11,514,434 ADS, equivalent to roughly 34.5 million ordinary shares, consolidating his status as a 10%+ shareholder.
• All transactions are coded “P” (open-market buy) and were made directly, with no derivative features other than the standard ADS-to-ordinary-share convertibility.

Insider buying by a large, long-term holder is typically interpreted as a positive sentiment signal, suggesting management or significant shareholders view current valuation as attractive. However, the dollar amount, while meaningful, is modest relative to the insider’s existing position, limiting immediate balance-sheet impact.

Positive

• 82,606 ADS (≈247,818 ordinary shares) purchased over three days, indicating insider confidence.
• Beneficial ownership climbs to 11.51 million ADS (≈34.5 million ordinary shares), reinforcing 10%+ stake alignment.

Negative

• None.

Insights

Securities Analyst

TL;DR: 10% owner adds ~83k ADS, strengthening already large stake – a modest but positive sentiment signal.

The filing shows Richard Ian Griffiths accumulated roughly US $0.5 million of SLN stock over three consecutive days at prices slightly below the recent US $6 trading range. Although the purchase represents less than 1% of his existing 11.5 million-ADS position, insider buys—even incremental—often precede favorable news or reflect valuation conviction. No sales were reported, and holding growth to 34.5 million ordinary shares underlines long-term alignment with other investors. From a liquidity standpoint, the total volume is small relative to market cap, so direct financial impact is limited; nevertheless, continued accumulation by a well-informed 10% holder is directionally bullish.

Portfolio Manager

TL;DR: Incremental insider buying supports bullish thesis but size is not game-changing.

Griffiths’ purchases modestly lift his stake, signalling ongoing confidence amid a depressed share price. While US $0.5 million is immaterial to enterprise value, insider alignment reduces agency risk and can catalyze sentiment among smaller holders. I classify this as ‘impactful’ from a behavioral finance lens: clusters of insider buys often precede positive catalysts such as pipeline read-outs or strategic partnerships. Still, investors should weigh the modest scale and lack of new fundamental disclosures; the trade does not alter cash runway or clinical timelines.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

FLOOR 1 LIBERATION STATION

ESPLANADE

(Street)

ST HELIER Y9 JE2 3AS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$5.84	06/22/2025		P		20,977		(1)	(1)	Ordinary Shares	62,931	(1)	11,452,805	D
American Depositary Shares	$5.88	06/23/2025		P		35,005		(1)	(1)	Ordinary Shares	105,015	(1)	11,487,810	D
American Depositary Shares	$6.12	06/24/2025		P		26,624		(1)	(1)	Ordinary Shares	79,872	(1)	11,514,434	D

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

	/s/ Richard Ian Griffiths	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Ian Griffiths buy?

He acquired 82,606 ADS between 22 and 24 June 2025.

What was the average purchase price paid by the insider?

Prices ranged from $5.84 to $6.12 per ADS, averaging roughly $5.97.

How much is the total dollar value of the insider purchases?

Approximately US $0.49 million based on reported prices.

What is the insider’s total holding after the transactions?

11,514,434 ADS, equivalent to about 34.5 million ordinary shares.

Why is insider buying significant for SLN investors?

Purchases by a 10%+ owner can signal confidence in future prospects and align interests with shareholders.